16:10 EDT Summit Therapeutics (SMMT) reports Q1 adjusted EPS (7c), consensus (7c)
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SMMT:
- Summit Therapeutics options imply 6.7% move in share price post-earnings
- Is SMMT a Buy, Before Earnings?
- Summit Therapeutics selloff Friday on data overdone, says H.C. Wainwright
- Summit Therapeutics Receives Buy Rating Amid Promising Ivonescimab Developments and Strategic Trials
- BMO says Keytruda ‘still reigns’ after ivonescimab survival data